good and Martine Thanks, morning, everyone.
continue Unituxin. by our a and strong and Tyvaso, with toward XX,XXX time, three At treprostinil year-over-year to our products, reach of third quarter the is goal for to with the At approximately the X,XXX patients very patients we we're growth we end on our approximately pleased revenue which the U.S., total products our said, goal. progress products X,XXX at XXxXX of As double-digit posted patients XX,XXX had coupled third on treprostinil highlighted U.S. to quarter, the the of Orenitram in puts end Martine our XXXX. same have outside about when XX,XXX-patient patients revenue, the therapies us which by toward our treprostinil
dive products, like three Orenitram. Tyvaso, quarter, performance to This the our treprostinil Remodulin underlying I'd and of into
approval by year. on in goal a and anticipation doubling Tyvaso So no therapy a we to with we Earlier number health Tyvaso. to last that and of path double X,XXX may to I'll begin the not patients This from PH-ILD received ultimately end care X,XXX that of assumes year, established linear. of this the to April, recognizes patient initiation of access impact be COVID-related the next practitioner importantly, the
and The third was with quarter the pleased second very we're quarter of PH-ILD thus our far. launch progress the
that prior they meantime, a patient federal approximately will with quarters. that a want be To program in putting We can coverage, apply quarter, on number way to reimbursement health over these next over the and our the three the of assistance is transition we commenced coverage But for eligible. Tyvaso the model of our to we are during of the decision. predict near-term I for mid-November. to end PH-ILD patients time. patients Tyvaso of X/X able growth XXXX. we of the to during access Medicare CMS anticipate patients to We X,XXX continued drivers goal doubling growing Tyvaso third the Tyvaso end, the by decision few CMS can't reimbursement obtain Once comment number the the timing us care of quarter, mention also to period open toward regarding through coverage Tyvaso the patients in ending on patients if Tyvaso-active
many and that physicians is their channel patient of for may approval are health assistance, though hearing the PH-ILD waiting through eligible coverage Even Tyvaso patients. The be reimbursement prescribing Medicare patients Tyvaso first federal are on care CMS driver of PH-ILD. the for we before
prescriptions related we historical Tyvaso somewhat To DPI from and is first prescriptions that then from our driver summer the of of majority than later the have expect treaters. no XXXX. been driver second to which we the the of to writers. growth is approval growth expect vast the see in final The And date, PAH ILD
been on saw IV been out in Moving generic of saw Remodulin, There are and learned we generic the last quarter, launch subcu we IV treprostinil to exactly that primarily subcutaneous Remodulin initial Medicaid which far the This Since new switch a played patients, launch, generic available. starts active like XXXX. back with quantity what we our bolus off our amount patient launch to became generic in now at have have to or in tapered patients has enter an these census. forced to our patient negligible of to generic has similar form and we adding so almost dual QX eligible Medicare fact, treprostinil. levels and are above as long-term subcu and trend patients transitions remain that we a
has were color continuing the second by have Finally, We've consistently we quarter strong to saw investor quarter. especially feedback about Orenitram. the these calls patient from of with into year I'll regarding expansion, some highest Orenitram and following of quarters value prescribers into And was mentioned COVID. the Orenitram on FREEDOM-EV trajectory and previous in an label and we proposition, start In blunted able this efficacy. interactions conferences receiving physicians end FREEDOM-EV of the the about more Orenitram third we're launch over of patients the translated momentum its around the third positive on data. provide last the new the two And quarter, uptick number as this robust the that while
its in to PH-ILD achieve by that making the ongoing the to X,XXX conclusion, Remodulin patient on of year, value proposition returning growth. Orenitram appreciation and track and continued with progress the So in momentum patients pleased on we're launch we're end next Tyvaso in around the and we're Tyvaso of
And that, back I'll call the Martine. so to over with you, turn
